Stifel Downgrades ChemoCentryx to Hold, Lowers Price Target to $52
Benzinga Newsdesk 4 years ago
NewsDowngradesPrice TargetAnalyst Ratings
Stifel analyst Dae Gon Ha downgrades ChemoCentryx (NASDAQ:CCXI) from Buy to Hold and lowers the price target from $86 to $52.
Stifel analyst Dae Gon Ha downgrades ChemoCentryx (NASDAQ:CCXI) from Buy to Hold and lowers the price target from $86 to $52.